secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001104659-23-055028
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Pharma Q1 net loss narrows to $13.5M; TAVALISSE sales up 38% to $22.3M
----------------------------------------------------------------------------

- Net loss of $13.5M ($0.08/sh) improved from $27.4M ($0.16) in Q1 2022.
- Total revenue $26.1M: TAVALISSE $22.3M (+38% YoY), REZLIDHIA $1.5M (first full quarter).
- Shipped 2,256 TAVALISSE bottles to patients (highest quarter); 109 REZLIDHIA bottles shipped.
- Accessed $20M term loan from MidCap; cash and investments $58.7M as of March 31.
- Partner Kissei launched TAVALISSE in Japan; Lilly to begin Phase 2a trial of R552 in RA in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/0001104659-23-055028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/tm2314346d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-055028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer